An update on antifungal targets and mechanisms of resistance in Candidaalbicans

References

• Houten SM, Waterham HR. Nonorthologous gene displacement of phosphomevalonate kinase. Mol Genet Metab 2001; 72: 273–276
   Google Scholar
• Tsay YH, Robinson GW. Cloning and characterization of ERG8, an essential gene of Saccharomyces cerevisiae that encodes phosphomevalonate kinase. Mol Cell Biol 1991; 11: 620–631
   PubMedGoogle Scholar
• Roemer T, Jiang B, Davison J, et al. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol 2003; 50: 167–181
   PubMed Web of Science ®Google Scholar
• Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem Biophys Res Commun 1995; 207: 910–915
   PubMed Web of Science ®Google Scholar
• Watson PF, Rose ME, Ellis SW, England H, Kelly SL. Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals. Biochem Biophys Res Commun 1989; 164: 1170–1175
   PubMed Web of Science ®Google Scholar
• Lamb D, Kelly D, Kelly S. Molecular aspects of azole antifungal action and resistance. Drug Resist Updat 1999; 2: 390–402
   PubMed Web of Science ®Google Scholar
• Bard M, Lees ND, Turi T, et al. Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 1993; 28: 963–967
   PubMedGoogle Scholar
• Shimokawa O, Kato Y, Nakayama H. Increased drug sensitivity in Candida albicans cells accumulating 14-methylated sterols. J Med Vet Mycol 1986; 24: 481–483
   Google Scholar
• Bard M, Lees ND, Barbuch RJ, Sanglard D. Characterization of a cytochrome P450 deficient mutant of Candida albicans. Biochem Biophys Res Commun 1987; 147: 794–800
   PubMed Web of Science ®Google Scholar
• Shimokawa O, Nakayama H. A Candida albicans mutant conditionally defective in sterol 14 alpha- demethylation. J Med Vet Mycol 1989; 27: 121–125
   Google Scholar
• Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004; 48: 2124–2131
   PubMed Web of Science ®Google Scholar
• Marichal P, Koymans L, Willemsens S, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145: 2701–2713
   PubMed Web of Science ®Google Scholar
• Xiao L, Madison V, Chau AS, et al. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004; 48: 568–574
   PubMed Web of Science ®Google Scholar
• Fukuoka T, Johnston DA, Winslow CA, et al. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003; 47: 1213–1219
   PubMed Web of Science ®Google Scholar
• Ji H, Zhang W, Zhou Y, et al. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 2000; 43: 2493–2505
   PubMed Web of Science ®Google Scholar
• Ji H, Zhang W, Zhang M, et al. Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. J Med Chem 2003; 46: 474–485
   PubMed Web of Science ®Google Scholar
• Macchiarulo A, Costantino G, Fringuelli D, et al. 1,4-Benzothiazine and 1,4-benzoxazine imidazole derivatives with antifungal activity: a docking study. Bioorg Med Chem 2002; 10: 3415–3423
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 1998; 42: 241–253
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Sagar N, Hirschi KD. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother 1999; 43: 2798–2800
   PubMed Web of Science ®Google Scholar
• Marichal P, Vanden Bossche H, Odds FC, et al. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1997; 41: 2229–2237
   PubMedGoogle Scholar
• vanden Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992; 36: 2602–2610
   PubMed Web of Science ®Google Scholar
• Du, W, Coaker, M, Sobel, JD, Akins, RA. Shuttle vectors for Candida, albicans: control of plasmid copy number and elevated expression of cloned genes. Curr Genet 2004; 45: 390–398. Epub 2004 Mar 18.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003; 47: 2404–2412
   PubMed Web of Science ®Google Scholar
• Kalb VF, Woods CW, Turi TG, et al. Primary structure of the P450 lanosterol demethylase gene from Saccharomyces cerevisiae. Dna 1987; 6: 529–537
   PubMedGoogle Scholar
• Geber A, Hitchcock CA, Swartz JE, et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 1995; 39: 2708–2717
   PubMed Web of Science ®Google Scholar
• Vanden Bossche, H, Dromer, F, Improvisi, I, et al., Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36((Suppl 1)): 119–128.
   PubMedGoogle Scholar
• Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501–517
   PubMed Web of Science ®Google Scholar
• White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382–402
   PubMed Web of Science ®Google Scholar
• Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob Agents Chemother 1998; 42: 1057–1061
   PubMed Web of Science ®Google Scholar
• Ryder, NS. Activity of terbinafine against serious fungal pathogens. Mycoses 1999; 42((Suppl 2)): 115–119.
   Google Scholar
• Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38: 161–168
   Google Scholar
• Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother 2003; 47: 956–964
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol 2003; 48: 959–976
   PubMed Web of Science ®Google Scholar
• Hiratani T, Yamaguchi H. [Cross-resistance of Candida albicans to several different families of antifungals with ergosterol biosynthesis-inhibiting activity]. Jpn J Antibiot 1994; 47: 125–128
   Google Scholar
• Klobucnikova V, Kohut P, Leber R, et al. Terbinafine resistance in a pleiotropic yeast mutant is caused by a single point mutation in the ERG1 gene. Biochem Biophys Res Commun 2003; 309: 666–671
   PubMedGoogle Scholar
• Leber R, Fuchsbichler S, Klobucnikova V, et al. Molecular mechanism of terbinafine resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2003; 47: 3890–3900
   Google Scholar
• Leber R, Landl K, Zinser E, et al. Dual localization of squalene epoxidase, Erg1p, in yeast reflects a relationship between the endoplasmic reticulum and lipid particles. Mol Biol Cell 1998; 9: 375–386
   Google Scholar
• Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2000; 44: 2693–2700
   PubMed Web of Science ®Google Scholar
• Liu W, May GS, Lionakis MS, Lewis RE, Kontoyiannis DP. Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. Antimicrob Agents Chemother 2004; 48: 2490–2496
   PubMedGoogle Scholar
• Gaber RF, Copple DM, Kennedy BK, Vidal M, Bard M. The yeast gene ERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol. Mol Cell Biol 1989; 9: 3447–3456
   PubMed Web of Science ®Google Scholar
• Kleinhans FW, Lees ND, Bard M, Haak RA, Woods RA. ESR determinations of membrane permeability in a yeast sterol mutant. Chem Phys Lipids 1979; 23: 143–154
   Google Scholar
• Bard M, Lees ND, Burrows LS, Kleinhans FW. Differences in crystal violet uptake and cation-induced death among yeast sterol mutants. J Bacteriol 1978; 135: 1146–1148
   PubMed Web of Science ®Google Scholar
• Welihinda AA, Beavis AD, Trumbly RJ. Mutations in LIS1 (ERG6) gene confer increased sodium and lithium uptake in Saccharomyces cerevisiae. Biochim Biophys Acta 1994; 1193: 107–117
   PubMed Web of Science ®Google Scholar
• Jensen-Pergakes KL, Kennedy MA, Lees ND, et al. Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility studies in erg6 mutants. Antimicrob Agents Chemother 1998; 42: 1160–1167
   PubMed Web of Science ®Google Scholar
• Kaur R, Bachhawat AK. The yeast multidrug resistance pump, Pdr5p, confers reduced drug resistance in erg mutants of Saccharomyces cerevisiae. Microbiology 1999; 145((Pt 4))809–818
   Google Scholar
• Jia N, Arthington-Skaggs B, Lee W, et al. Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. Antimicrob Agents Chemother 2002; 46: 947–957
   PubMed Web of Science ®Google Scholar
• Gachotte D, Pierson CA, Lees ND, et al. A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc Natl Acad Sci USA 1997; 94: 11173–11178
   PubMedGoogle Scholar
• Kennedy MA, Johnson TA, Lees ND, et al. Cloning and sequencing of the Candida albicans C-4 sterol methyl oxidase gene (ERG25) and expression of an ERG25 conditional lethal mutation in Saccharomyces cerevisiae. Pediatr Infect Dis J 2000; 19: 319–324
   Google Scholar
• Nose H, Fushimi H, Seki A, et al. PF1163A, a novel antifungal agent, inhibit ergosterol biosynthesis at C-4 sterol methyl oxidase. J Antibiot (Tokyo) 2002; 55: 969–974
   Google Scholar
• Nose H, Seki A, Yaguchi T, et al. PF1163A and B, new antifungal antibiotics produced by Penicillium sp. I. Taxonomy of producing strain, fermentation, isolation and biological activities. J Antibiot (Tokyo) 2000; 53: 33–37
   Google Scholar
• Bujdakova H, Kral'ova K, Sidoova E. Antifungal and antialgal activity of 3-(2-alkylthio-6-benzothiazolylaminomethyl)-2-benzoxazolinethi ones. Pharmazie 1995; 50: 156
   PubMed Web of Science ®Google Scholar
• Bujdakova H, Kuchta T, Sidoova E, Gvozdjakova A. Anti-Candida activity of four antifungal benzothiazoles. FEMS Microbiol Lett 1993; 112: 329–333
   PubMed Web of Science ®Google Scholar
• Kuchta T, Leka C, Farkas P, et al. Inhibition of sterol 4-demethylation in Candida albicans by 6-amino-2-n-pentylthiobenzothiazole, a novel mechanism of action for an antifungal agent. Antimicrob Agents Chemother 1995; 39: 1538–1541
   Google Scholar
• Kuchta T, Bartkova K, Kubinec R. Ergosterol depletion and 4-methyl sterols accumulation in the yeast Saccharomyces cerevisiae treated with an antifungal, 6-amino-2-n-pentylthiobenzothiazole. Biochem Biophys Res Commun 1992; 189: 85–91
   Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425–430
   PubMed Web of Science ®Google Scholar
• Basson ME, Thorsness M, Rine J. Saccharomyces cerevisiae contains two functional genes encoding 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Proc Natl Acad Sci USA 1986; 83: 5563–5567
   PubMed Web of Science ®Google Scholar
• Casey WM, Keesler GA, Parks LW. Regulation of partitioned sterol biosynthesis in Saccharomyces cerevisiae. J Bacteriol 1992; 174: 7283–7288
   PubMedGoogle Scholar
• Polakowski T, Stahl U, Lang C. Overexpression of a cytosolic hydroxymethylglutaryl-CoA reductase leads to squalene accumulation in yeast. Appl Microbiol Biotechnol 1998; 49: 66–71
   PubMed Web of Science ®Google Scholar
• Bard M, Lees ND, Burnett AS, Parker RA. Isolation and characterization of mevinolin resistant mutants of Saccharomyces cerevisiae. J Gen Microbiol 1988; 134: 1071–1078
   Google Scholar
• Song JL, Lyons CN, Holleman S, Oliver BG, White TC. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med Mycol 2003; 41: 417–425
   PubMed Web of Science ®Google Scholar
• Lorenz RT, Parks LW. Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother 1990; 349: 1660–1665
   Google Scholar
• Dimster-Denk D, Rine J, Phillips J, et al. Comprehensive evaluation of isoprenoid biosynthesis regulation in Saccharomyces cerevisiae utilizing the Genome Reporter Matrix(TM). J Lipid Res 1999; 40: 850–860
   PubMedGoogle Scholar
• Brutyan RA, McPhie P. On the one-sided action of amphotericin B on lipid bilayer membranes. J Gen Physiol 1996; 107: 69–78
   PubMed Web of Science ®Google Scholar
• Langlet J, Berges J, Caillet J, Demaret JP. Theoretical study of the complexation of amphotericin B with sterols. Biochimica et Biophysica Acta 1994; 1191: 79–93
   Google Scholar
• Vazquez JA, Arganoza MT, Boikov D, et al. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles. J Clin Microbiol 1998; 36: 2690–2695
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Arganoza MT, Vaishampayan JK, Akins RA. In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrob Agents Chemother 1996; 40: 2511–2516
   PubMed Web of Science ®Google Scholar
• Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002; 46: 3208–3214
   PubMed Web of Science ®Google Scholar
• Sokol-Anderson M, Sligh JE, Jr, Elberg S, et al. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 1988; 32: 702–705
   PubMed Web of Science ®Google Scholar
• Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients [letter]. Lancet 1996; 348: 1523–1524
   PubMed Web of Science ®Google Scholar
• Kelly SL, Lamb DC, Kelly DE, et al. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett 1997; 400: 80–82
   PubMed Web of Science ®Google Scholar
• Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997; 41: 196–199
   PubMed Web of Science ®Google Scholar
• O'Keeffe J, Kavanagh K. Adriamycin alters the expression of drug efflux pumps and confers amphotericin B tolerance in Candida albicans. Anticancer Res 2004; 24(2A)405–408
   Google Scholar
• Gale EF, Johnson AM, Kerridge D, Koh TY. Factors affecting the changes in amphotericin sensitivity of Candida albicans during growth. J Gen Microbiol 1975; 87: 20–36
   PubMedGoogle Scholar
• Gale EF, Ingram J, Kerridge D, Notario V, Wayman F. Reduction of amphotericin resistance in stationary phase cultures of Candida albicans by treatment with enzymes. J Gen Microbiol 1980; 117: 383–391
   Google Scholar
• Gale EF, Johnson AM, Kerridge D, Wayman F. Phenotypic resistance to miconazole and amphotericin B in Candida albicans. J Gen Microbiol 1980; 117: 535–538
   PubMedGoogle Scholar
• Cassone A, Kerridge D, Gale EF. Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J Gen Microbiol 1979; 110: 339–349
   Google Scholar
• Yoon SA, Vazquez JA, Steffan PE, Sobel JD, Akins RA. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother 1999; 43: 836–845
   PubMed Web of Science ®Google Scholar
• Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol 1999; 43: 1017–1025
   PubMed Web of Science ®Google Scholar
• Barker KS, Crisp S, Wiederhold N, et al. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J Antimicrob Chemother 2004; 54: 376–385
   PubMed Web of Science ®Google Scholar
• Dimster-Denk D, Thorsness MK, Rine J. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in Saccharomyces cerevisiae. Mol Biol Cell 1994; 5: 655–665
   PubMedGoogle Scholar
• Soustre I, Dupuy PH, Silve S, Karst F, Loison G. Sterol metabolism and ERG2 gene regulation in the yeast Saccharomyces cerevisiae. FEBS Lett 2000; 470: 102–106
   PubMedGoogle Scholar
• Smith SJ, Crowley JH, Parks LW. Transcriptional regulation by ergosterol in the yeast Saccharomyces cerevisiae. Mol Cell Biol 1996; 16: 5427–5432
   PubMedGoogle Scholar
• Kennedy MA, Barbuch R, Bard M. Transcriptional regulation of the squalene synthase gene (ERG9) in the yeast Saccharomyces cerevisiae. Biochim Biophys Acta 1999; 1445: 110–122
   PubMedGoogle Scholar
• Arthington-Skaggs BA, Crowell DN, Yang H, Sturley SL, Bard M. Positive and negative regulation of a sterol biosynthetic gene (ERG3) in the post-squalene portion of the yeast ergosterol pathway. FEBS Let 1996; 392: 161–165
   PubMedGoogle Scholar
• Hornby JM, Jensen EC, Lisec AD, et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001; 67: 2982–2992
   PubMed Web of Science ®Google Scholar
• Hornby JM, Nickerson KW. Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother 2004; 48: 2305–2307
   PubMed Web of Science ®Google Scholar
• Hornby JM, Kebaara BW, Nickerson KW. Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid B. Antimicrob Agents Chemother 2003; 47: 2366–2369
   PubMed Web of Science ®Google Scholar
• Pierson CA, Eckstein J, Barbuch R, Bard M. Ergosterol gene expression in wild-type and ergosterol-deficient mutants of Candida albicans. Med Mycol 2004; 42: 385–389
   PubMed Web of Science ®Google Scholar
• Henry KW, Nickels JT, Edlind TD. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2000; 44: 2693–2700
   PubMed Web of Science ®Google Scholar
• Smith WL, Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002; 46: 3532–3539
   PubMed Web of Science ®Google Scholar
• Song JL, Harry JB, Eastman RT, Oliver BG, White TC. The Candida albicans lanosterol 14-alpha-demethylase (ERG11) gene promoter is maximally induced after prolonged growth with antifungal drugs. Antimicrob Agents Chemother 2004; 48: 1136–1144
   Google Scholar
• De Backer MD, Ilyina T, Ma XJ, et al. Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray. Antimicrob Agents Chemother 2001; 45: 1660–1670
   PubMed Web of Science ®Google Scholar
• Karababa M, Coste AT, Rognon B, Bille J, Sanglard D. Comparison of gene expression profiles of Candida albicans azole-resistant clinical isolates and laboratory strains exposed to drugs inducing multidrug transporters. Antimicrob Agents Chemother 2004; 48: 3064–3079
   PubMed Web of Science ®Google Scholar
• Cowen LE, Nantel A, Whiteway MS, et al. Population genomics of drug resistance in Candida albicans. Proc Natl Acad Sci USA 2002; 99: 9284–9289
   Google Scholar
• Rogers PD, Barker KS. Genome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother 2003; 47: 1220–1227
   PubMed Web of Science ®Google Scholar
• Barker KS, Pearson MM, Rogers PD. Identification of genes differentially expressed in association with reduced azole susceptibility in Saccharomyces cerevisiae. J Antimicrob Chemother 2003; 51: 1131–1140
   PubMed Web of Science ®Google Scholar
• Silver PM, Oliver BG, White TC. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot Cell 2004; 3: 1391–1397
   PubMed Web of Science ®Google Scholar
• Henry KW, Nickels JT, Edlind TD. ROX1 and ERG Regulation in Saccharomyces cerevisiae: Implications for Antifungal Susceptibility. Eukaryotic Cell 2002; 1: 1041–1044
   Google Scholar
• Lo HJ, Wang JS, Lin CY, et al. Efg1 Involved in Drug Resistance by Regulating the Expression of ERG3 in Candida albicans. Antimicrob Agents Chemother 2005; 49: 1213–1215
   PubMed Web of Science ®Google Scholar
• Lewis RE, Lo HJ, Raad II, Kontoyiannis DP. Lack of catheter infection by the efg1/efg1 cph1/cph1 double-null mutant, a Candida albicans strain that is defective in filamentous growth. Antimicrob Agents Chemother 2002; 46: 1153–1155
   PubMed Web of Science ®Google Scholar
• Lo HJ, Kohler JR, DiDomenico B, et al. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90: 939–949
   PubMed Web of Science ®Google Scholar
• Stoldt VR, Sonneborn A, Leuker CE, Ernst JF. Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. Embo J 1997; 16: 1982–1991
   PubMed Web of Science ®Google Scholar
• van den Hazel HB, Pichler H, do Valle Matta MA, et al. PDR16 and PDR17, two homologous genes of Saccharomyces cerevisiae, affect lipid biosynthesis and resistance to multiple drugs. J Biol Chem 1999; 274: 1934–1941
   Google Scholar
• Kennedy MA, Bard M. Positive and negative regulation of squalene synthase (ERG9), an ergosterol biosynthetic gene, in Saccharomyces cerevisiae. Biochim Biophys Acta 2001; 1517: 177–189
   Google Scholar
• Prasad R, De Wergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Current Genetics 1995; 27: 320–329
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143((Pt 2))405–416
   Google Scholar
• Prasad R, Kapoor K. Multidrug resistance in yeast Candida. Int Rev Cytol 2005; 242: 215–248
   PubMedGoogle Scholar
• Krishnamurthy S, Chatterjee U, Gupta V, et al. Deletion of transmembrane domain 12 of CDR1, a multidrug transporter from Candida albicans, leads to altered drug specificity: expression of a yeast multidrug transporter in baculovirus expression system. Yeast 1998; 14: 535–550
   Google Scholar
• Niimi M, Niimi K, Takano Y, et al. Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance. J Antimicrob Chemother 2004; 54: 999–1006
   PubMed Web of Science ®Google Scholar
• Bauer BE, Wolfger H, Kuchler K. Inventory and function of yeast ABC proteins: about sex, stress, pleiotropic drug and heavy metal resistance. Biochim Biophys Acta 1999; 1461: 217–236
   PubMed Web of Science ®Google Scholar
• Jones T, Federspiel NA, Chibana H, et al. The diploid genome sequence of Candida albicans. Proc Natl Acad Sci USA 2004; 101: 7329–7334
   PubMed Web of Science ®Google Scholar
• Nakamura K, Niimi M, Niimi K, et al. Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob Agents Chemother 2001; 45: 3366–3374
   PubMed Web of Science ®Google Scholar
• Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int J Antimicrob Agents 2003; 22: 291–300
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300–2305
   PubMed Web of Science ®Google Scholar
• Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998; 42: 2932–2937
   PubMed Web of Science ®Google Scholar
• White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1488–1494
   PubMed Web of Science ®Google Scholar
• Maebashi K, Niimi M, Kudoh M, et al. Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. J Antimicrob Chemother 2001; 47: 527–536
   PubMedGoogle Scholar
• White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46: 1704–1713
   PubMed Web of Science ®Google Scholar
• Anderson JB, Sirjusingh C, Parsons AB, et al. Mode of selection and experimental evolution of antifungal drug resistance in Saccharomyces cerevisiae. Genetics 2003; 163: 1287–1298
   PubMed Web of Science ®Google Scholar
• Cowen LE, Sanglard D, Calabrese D, et al. Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 2000; 182: 1580–1591
   Google Scholar
• Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143((Pt 2))405–416
   Google Scholar
• Balan I, Alarco AM, Raymond M. The Candida albicans CDR3 gene codes for an opaque-phase ABC transporter. J Bacteriol 1997; 179: 7210–7218
   Google Scholar
• Franz R, Michel S, Morschh#user J. A fourth gene from the Candida albicans CDR family of ABC transporters. Curr Microbiol 1998; 37: 359–361
   Google Scholar
• Jha S, Dabas N, Karnani N, Saini P, Prasad R. ABC multidrug transporter Cdr1p of Candida albicans has divergent nucleotide-binding domains which display functional asymmetry. FEMS Yeast Res 2004; 5: 63–72
   PubMed Web of Science ®Google Scholar
• Shukla S, Ambudkar SV, Prasad R. Substitution of threonine-1351 in the multidrug transporter Cdr1p of Candida albicans results in hypersusceptibility to antifungal agents and threonine-1351 is essential for synergic effects of calcineurin inhibitor FK520. J Antimicrob Chemother 2004; 54: 38–45
   Google Scholar
• Egner R, Bauer BE, Kuchler K. The transmembrane domain 10 of the yeast Pdr5p ABC antifungal efflux pump determines both substrate specificity and inhibitor susceptibility. Mol Microbiol 2000; 35: 1255–1263
   Google Scholar
• Maesaki S, Marichal P, Vanden Bossche H, Sanglard D, Kohno S. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother 1999; 44: 27–31
   PubMedGoogle Scholar
• Shukla S, Saini P, Smriti, et al. Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell 2003; 2: 1361–1375
   Google Scholar
• Gauthier C, Weber S, Alarco AM, et al. Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. Antimicrob Agents Chemother 2003; 47: 1543–1554
   PubMed Web of Science ®Google Scholar
• Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. International Journal of Antimicrobial Agents 2003; 22: 291–300
   PubMed Web of Science ®Google Scholar
• Wada S, Niimi M, Niimi K, et al. Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties. J Biol Chem 2002; 277: 46809–46821
   Google Scholar
• Wada S, Tanabe K, Yamazaki A, et al. Phosphorylation of Candida glabrata ATP-binding cassette transporter Cdr1p regulates drug efflux activity and ATPase stability. J Biol Chem 2005; 280: 94–103
   Google Scholar
• Sauna ZE, Peng XH, Nandigama K, Tekle S, Ambudkar SV. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol 2004; 65: 675–684
   PubMed Web of Science ®Google Scholar
• Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 2000; 92: 898–902
   PubMed Web of Science ®Google Scholar
• Shukla S, Sauna ZE, Prasad R, Ambudkar SV. Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans. Biochem Biophys Res Commun 2004; 322: 520–525
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Gupta V, Prasad R, Panwar SL. Expression of CDR1, a multidrug resistance gene of Candida albicans: transcriptional activation by heat shock, drugs and human steroid hormones. FEMS Microbiol Lett 1998; 160: 191–197
   Google Scholar
• Hernaez ML, Gil C, Pla J, Nombela C. Induced expression of the Candida albicans multidrug resistance gene CDR1 in response to fluconazole and other antifungals. Yeast 1998; 14: 517–526
   PubMed Web of Science ®Google Scholar
• Puri N, Krishnamurthy S, Habib S, et al. CDR1, a multidrug resistance gene from Candida albicans, contains multiple regulatory domains in its promoter and the distal AP-1 element mediates its induction by miconazole. FEMS Microbiol Lett 1999; 180: 213–219
   Google Scholar
• Gaur NA, Puri N, Karnani N, et al. Identification of a negative regulatory element which regulates basal transcription of a multidrug resistance gene CDR1 of Candida albicans. FEMS Yeast Res 2004; 4: 389–399
   Google Scholar
• de Micheli M, Bille J, Schueller C, Sanglard D. A common drug-responsive element mediates the upregulation of the Candida albicans ABC transporters CDR1 and CDR2, two genes involved in antifungal drug resistance. Mol Microbiol 2002; 43: 1197–214
   PubMed Web of Science ®Google Scholar
• Karnani N, Gaur NA, Jha S, et al. SRE1 and SRE2 are two specific steroid-responsive modules of Candida drug resistance gene 1 (CDR1) promoter. Yeast 2004; 21: 219–239
   PubMed Web of Science ®Google Scholar
• Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell 2004; 3: 1639–1652
   PubMed Web of Science ®Google Scholar
• Rustad TR, Stevens DA, Pfaller MA, White TC. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology 2002; 148: 1061–1072
   PubMed Web of Science ®Google Scholar
• Chen CG, Yang YL, Shih HI, Su CL, Lo HJ. CaNdt80 is involved in drug resistance in Candida albicans by regulating CDR1. Antimicrob Agents Chemother 2004; 48: 4505–4512
   PubMed Web of Science ®Google Scholar
• Alarco AM, Balan I, Talibi D, Mainville N, Raymond M. AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily. J Biol Chem 1997; 272: 19304–19313
   PubMed Web of Science ®Google Scholar
• Alarco AM, Raymond M. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J Bacteriol 1999; 181: 700–708
   PubMed Web of Science ®Google Scholar
• Delaveau T, Delahodde A, Carvajal E, Subik J, Jacq C. PDR3, a new yeast regulatory gene, is homologous to PDR1 and controls the multidrug resistance phenomenon. Mol Gen Genet 1994; 244: 501–511
   PubMedGoogle Scholar
• Katzmann DJ, Burnett PE, Golin J, Mahe Y, Moye-Rowley WS. Transcriptional control of the yeast PDR5 gene by the PDR3 gene product. Mol Cell Biol 1994; 14: 4653–4661
   PubMedGoogle Scholar
• Balzi E, Chen W, Ulaszewski S, Capieaux E, Goffeau A. The multidrug resistance gene PDR1 from Saccharomyces cerevisiae. J Biol Chem 1987; 262: 16871–16879
   PubMed Web of Science ®Google Scholar
• Meyers S, Schauer W, Balzi E, et al. Interaction of the yeast pleiotropic drug resistance genes PDR1 and PDR5. Curr Genet 1992; 21: 431–436
   PubMedGoogle Scholar
• Balzi E, Wang M, Leterme S, Van Dyck L, Goffeau A. PDR5, a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1. J Biol Chem 1994; 269: 2206–2214
   PubMed Web of Science ®Google Scholar
• Talibi D, Raymond M. Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. J Bacteriol 1999; 181: 231–240
   PubMed Web of Science ®Google Scholar
• Yang X, Talibi D, Weber S, Poisson G, Raymond M. Functional isolation of the Candida albicans FCR3 gene encoding a bZip transcription factor homologous to Saccharomyces cerevisiae Yap3p. Yeast 2001; 18: 1217–1225
   Google Scholar
• Hallstrom TC, Katzmann DJ, Torres RJ, Sharp WJ, Moye-Rowley WS. Regulation of transcription factor Pdr1p function by an Hsp70 protein in Saccharomyces cerevisiae. Mol Cell Biol 1998; 18: 1147–1155
   PubMed Web of Science ®Google Scholar
• Kim DY, Song WY, Yang YY, Lee Y. The role of PDR13 in tolerance to high copper stress in budding yeast. FEBS Lett 2001; 508: 99–102
   Google Scholar
• Hallstrom TC, Moye-Rowley WS. Hyperactive forms of the Pdr1p transcription factor fail to respond to positive regulation by the hsp70 protein Pdr13p. Mol Microbiol 2000; 36: 402–413
   Google Scholar
• Michimoto T, Aoki T, Toh-e A, Kikuchi Y. Yeast Pdr13p and Zuo1p molecular chaperones are new functional Hsp70 and Hsp40 partners. Gene 2000; 257: 131–137
   Google Scholar
• Eisenman HC, Craig EA. Activation of pleiotropic drug resistance by the J-protein and Hsp70-related proteins, Zuo1 and Ssz1. Mol Microbiol 2004; 53: 335–344
   Google Scholar
• Aleman C, Annereau JP, Liang XJ, et al. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 2003; 63: 3084–3091
   PubMedGoogle Scholar
• Luker GD, Pica CM, Kumar AS, Covey DF, Piwnica-Worms D. Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry 2000; 39: 7651–7661
   Google Scholar
• Troost J, Lindenmaier H, Haefeli WE, Weiss J. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol 2004; 66: 1332–1339
   PubMed Web of Science ®Google Scholar
• Ghetie MA, Marches R, Kufert S, Vitetta ES. An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood 2004; 104: 178–183
   PubMed Web of Science ®Google Scholar
• Malinska K, Malinsky J, Opekarova M, Tanner W. Distribution of Can1p into stable domains reflects lateral protein segregation within the plasma membrane of living S. cerevisiae cells. J Cell Sci 2004; 117: 6031–6041
   PubMed Web of Science ®Google Scholar
• Li Y, Prinz WA. ATP-binding cassette (ABC) transporters mediate nonvesicular, raft-modulated sterol movement from the plasma membrane to the endoplasmic reticulum. J Biol Chem 2004; 279: 45226–45234
   Google Scholar
• Hearn JD, Lester RL, Dickson RC. The uracil transporter Fur4p associates with lipid rafts. J Biol Chem 2003; 278: 3679–3686
   PubMedGoogle Scholar
• Bagnat M, Chang A, Simons K. Plasma membrane proton ATPase Pma1p requires raft association for surface delivery in yeast. Mol Biol Cell 2001; 12: 4129–4138
   PubMedGoogle Scholar
• Bagnat M, Keranen S, Shevchenko A, Shevchenko A, Simons K. Lipid rafts function in biosynthetic delivery of proteins to the cell surface in yeast. Proc Natl Acad Sci USA 2000; 97: 3254–3259
   PubMed Web of Science ®Google Scholar
• Moffett S, Brown DA, Linder ME. Lipid-dependent targeting of G proteins into rafts. J Biol Chem 2000; 275: 2191–2198
   PubMed Web of Science ®Google Scholar
• Malinska K, Malinsky J, Opekarova M, Tanner W. Visualization of protein compartmentation within the plasma membrane of living yeast cells. Mol Biol Cell 2003; 14: 4427–4436
   PubMed Web of Science ®Google Scholar
• Dogra S, Krishnamurthy S, Gupta V, et al. Asymmetric distribution of phosphatidylethanolamine in C. albicans: possible mediation by CDR1, a multidrug transporter belonging to ATP binding cassette (ABC) superfamily. Yeast 1999; 15: 111–121
   PubMed Web of Science ®Google Scholar
• Smriti AA, Krishnamurthy SS, Prasad R. Membrane fluidity affects functions of Cdr1p, a multidrug ABC transporter of Candida albicans [published erratum appears in FEMS Microbiol Lett 1;176:263]. FEMS Microbiol Lett 1999; 173: 475–481
   Google Scholar
• Mukhopadhyay K, Prasad T, Saini P, et al. Membrane sphingolipid-ergosterol interactions are important determinants of multidrug resistance in Candida albicans. Antimicrob Agents Chemother 2004; 48: 1778–1787
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay K, Kohli A, Prasad R. Drug susceptibilities of yeast cells are affected by membrane lipid composition. Antimicrob Agents Chemother 2002; 46: 3695–3705
   PubMed Web of Science ®Google Scholar
• Kohli A, Smriti, Mukhopadhyay K, Rattan A, Prasad R. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrob Agents Chemother 2002; 46: 1046–1052
   PubMed Web of Science ®Google Scholar
• Sa-Correia I, Tenreiro S. The multidrug resistance transporters of the major facilitator superfamily, 6 years after disclosure of Saccharomyces cerevisiae genome sequence. J Biotechnol 2002; 98: 215–226
   PubMed Web of Science ®Google Scholar
• Ben-Yaacov R, Knoller S, Caldwell GA, Becker JM, Koltin Y. Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrob Agents Chemother 1994; 38: 648–652
   PubMedGoogle Scholar
• Fling ME, Kopf J, Tamarkin A, et al. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Molecular & General Genetics 1991; 227: 318–329
   PubMedGoogle Scholar
• Kohli A, Gupta V, Krishnamurthy S, Hasnain SE, Prasad R. Specificity of drug transport mediated by CaMDR1: a major facilitator of Candida albicans. J Biosci 2001; 26: 333–339
   PubMed Web of Science ®Google Scholar
• Wirsching S, Michel S, Morschhauser J. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol 2000; 36: 856–865
   PubMed Web of Science ®Google Scholar
• Morschhauser J, Michel S, Staib P. Sequential gene disruption in Candida albicans by FLP-mediated site-specific recombination. Mol Microbiol 1999; 32: 547–556
   PubMed Web of Science ®Google Scholar
• Calabrese D, Bille J, Sanglard D. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 2000; 146: 2743–2754
   PubMed Web of Science ®Google Scholar
• Gupta V, Kohli A, Krishnamurthy S, et al. Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation. Curr Genet 1998; 34: 192–199
   Google Scholar
• Wirsching S, Michel S, Kohler G, Morschhauser J. Activation of the multiple drug resistance gene MDR1 in fluconazole-resistant, clinical Candida albicans strains is caused by mutations in a trans-regulatory factor. J Bacteriol 2000; 182: 400–404
   PubMed Web of Science ®Google Scholar
• Moosa MY, Sobel JD, Elhalis H, Du W, Akins RA. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium. Antimicrob Agents Chemother 2004; 48: 161–167
   PubMedGoogle Scholar
• Hooshdaran MZ, Barker KS, Hilliard GM, et al. Proteomic analysis of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother 2004; 48: 2733–2735
   PubMed Web of Science ®Google Scholar
• Kusch H, Biswas K, Schwanfelder S, et al. A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. Mol Genet Genomics 2004; 271: 554–565
   Google Scholar
• Krcmery V, Huttova M, Mateicka F, et al. Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro. J Antimicrob Chemother 2001; 48: 521–525
   PubMed Web of Science ®Google Scholar
• Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47: 34–38
   PubMed Web of Science ®Google Scholar
• Maxwell MJ, Messer SA, Hollis RJ, et al. Evaluation of Etest method for determining fluconazole and voriconazole MICs for 279 clinical isolates of Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 1087–1090
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298–1302
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 1997 to 2000; 40: 852–856
   Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254–3259
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419–4431
   PubMed Web of Science ®Google Scholar
• Pfaller, MA, Diekema, DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10((Suppl 1)): 11–23.
   PubMedGoogle Scholar
• Kovacicova G, Mateicka F, Hanzen J, et al. Breakthrough candidaemias during empirical therapy with fluconazole in non-cancer and non-HIV adults caused by in vitro-susceptible Candida spp.: report of 33 cases. Scand J Infect Dis 2001; 33: 749–751
   PubMed Web of Science ®Google Scholar
• Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002; 21: 209–211
   PubMed Web of Science ®Google Scholar
• Uzun, O, Ascioglu, S, Anaissie, EJ, Rex, JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32: 1713–1717. Epub 2001 May 7.
   PubMed Web of Science ®Google Scholar
• Perepnikhatka V, Fischer FJ, Niimi M, et al. Specific chromosome alterations in fluconazole-resistant mutants of Candida albicans. J Bacteriol 1999; 181: 4041–4049
   PubMed Web of Science ®Google Scholar
• Sobel JD. Treatment of vaginal Candida infections. Expert Opin Pharmacother 2002; 3: 1059–1065
   PubMedGoogle Scholar
• Pfaller MA, Rhine-Chalberg J, Redding SW, et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994; 32: 59–64
   PubMed Web of Science ®Google Scholar
• Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999; 59: 91–95
   PubMed Web of Science ®Google Scholar
• Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 351: 876–883
   PubMed Web of Science ®Google Scholar
• Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother 1997; 41: 535–539
   PubMedGoogle Scholar
• Marr KA, Lyons CN, Rustad T, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 1998; 42: 2645–2649
   Google Scholar
• Marr KA, Lyons CN, Rustad TR, et al. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR [published erratum appears in Antimicrob Agents Chemother Feb;43:438]. Antimicrob Agents Chemother 1998; 42: 2584–2589
   PubMed Web of Science ®Google Scholar
• Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 2001; 45: 52–59
   PubMed Web of Science ®Google Scholar
• Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother 1997; 41: 535–539
   PubMedGoogle Scholar
• Soll DR. High-frequency switching in Candida albicans. Clin Microbiol Rev 1992; 5: 183–203
   PubMed Web of Science ®Google Scholar
• Soll DR, Galask R, Isley S, et al. Switching of Candida albicans during successive episodes of recurrent vaginitis. J Clin Microbiol 1989; 27: 681–690
   PubMed Web of Science ®Google Scholar
• Soll DR. High-frequency switching in Candida albicans and its relations to vaginal candidiasis. Am J Obstet Gynecol 1988; 158: 997–1001
   PubMed Web of Science ®Google Scholar
• Zhao R, Lockhart SR, Daniels K, Soll DR. Roles of TUP1 in switching, phase maintenance, and phase-specific gene expression in Candida albicans. Eukaryot Cell 2002; 1: 353–365
   Google Scholar
• Srikantha T, Tsai L, Daniels K, Klar AJ, Soll DR. The histone deacetylase genes HDA1 and RPD3 play distinct roles in regulation of high-frequency phenotypic switching in Candida albicans. J Bacteriol 2001; 183: 4614–4625
   PubMed Web of Science ®Google Scholar
• Klar AJ, Srikantha T, Soll DR. A histone deacetylation inhibitor and mutant promote colony-type switching of the human pathogen Candida albicans. Genetics 2001; 158: 919–924
   PubMedGoogle Scholar
• Soll DR. Gene regulation during high-frequency switching in Candida albicans. Microbiology 1997; 143((Pt 2))279–288
   Google Scholar
• Soll DR, Morrow B, Srikantha T, Vargas K, Wertz P. Developmental and molecular biology of switching in Candida albicans. Oral Surg Oral Med Oral Pathol 1994; 78: 194–201
   Google Scholar
• Vargas K, Messer SA, Pfaller M, et al. Elevated phenotypic switching and drug resistance of Candida albicans from human immunodeficiency virus-positive individuals prior to first thrush episode. J Clin Microbiol 2000; 38: 3595–3607
   PubMed Web of Science ®Google Scholar
• Marr KA, Rustad TR, Rex JH, White TC. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 1999; 43: 1383–1386
   PubMed Web of Science ®Google Scholar
• Revankar SG, Kirkpatrick WR, McAtee RK, et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 1998; 36: 153–156
   PubMed Web of Science ®Google Scholar
• Lee MK, Williams LE, Warnock DW, Arthington-Skaggs BA. Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother 2004; 53: 217–224
   PubMedGoogle Scholar
• Rex JH, Nelson PW, Paetznick VL, et al. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129–134
   PubMed Web of Science ®Google Scholar
• Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000; 80: 1483–1521
   PubMed Web of Science ®Google Scholar
• Bader T, Bodendorfer B, Schroppel K, Morschhauser J. Calcineurin is essential for virulence in Candida albicans. Infect Immun 2003; 71: 5344–5354
   PubMed Web of Science ®Google Scholar
• Maesaki S, Marichal P, Hossain MA, et al. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. J Antimicrob Chemother 1998; 42: 747–753
   PubMed Web of Science ®Google Scholar
• Cruz MC, Goldstein AL, Blankenship JR, et al. Calcineurin is essential for survival during membrane stress in Candida albicans. Embo J 2002; 21: 546–559
   PubMed Web of Science ®Google Scholar
• Marchetti O, Moreillon P, Entenza JM, et al. Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob Agents Chemother 2003; 47: 1565–1570
   PubMed Web of Science ®Google Scholar
• Cameron AM, Steiner JP, Roskams AJ, et al. Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux. Cell 1995; 83: 463–472
   PubMed Web of Science ®Google Scholar
• Onyewu C, Wormley FL, Jr, Perfect JR, Heitman J. The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infect Immun 2004; 72: 7330–7333
   PubMed Web of Science ®Google Scholar
• Thevelein JM, de Winde JH. Novel sensing mechanisms and targets for the cAMP-protein kinase A pathway in the yeast Saccharomyces cerevisiae. Mol Microbiol 1999; 33: 904–918
   PubMed Web of Science ®Google Scholar
• Kafadar KA, Cyert MS. Integration of stress responses: modulation of calcineurin signaling in Saccharomyces cerevisiae by protein kinase. A Eukaryot Cell 2004; 3: 1147–1153
   PubMedGoogle Scholar
• Jain P, Akula I, Edlind T. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 2003; 47: 3195–3201
   PubMed Web of Science ®Google Scholar
• do Valle Matta MA, Jonniaux JL, Balzi E, Goffeau A, van den Hazel B. Novel target genes of the yeast regulator Pdr1p: a contribution of the TPO1 gene in resistance to quinidine and other drugs. Gene 2001; 272: 111–119
   PubMed Web of Science ®Google Scholar
• De Deken X, Raymond M. Constitutive activation of the PDR16 promoter in a Candida albicans azole-resistant clinical isolate overexpressing CDR1 and CDR2. Antimicrob Agents Chemother 2004; 48: 2700–2703
   Google Scholar
• Panwar SL, Krishnamurthy S, Gupta V, et al. CaALK8, an alkane assimilating cytochrome P450, confers multidrug resistance when expressed in a hypersensitive strain of Candida albicans. Yeast 2001; 18: 1117–1129
   Google Scholar
• Noel T, Francois F, Paumard P, et al. Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter. Antimicrob Agents Chemother 2003; 47: 1275–1284
   Google Scholar
• Albertson GD, Niimi M, Cannon RD, Jenkinson HF. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 1996; 40: 2835–2841
   PubMed Web of Science ®Google Scholar
• Maebashi K, Kudoh M, Nishiyama Y, et al. A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient. Microbiol Immunol 2002; 46: 317–326
   Google Scholar
• Fox TD, Folley LS, Mulero JJ, et al. Analysis and manipulation of yeast mitochondrial genes. Methods Enzymol 1991; 194: 149–165
   PubMed Web of Science ®Google Scholar
• O'Connor RM, McArthur CR, Clark-Walker GD. Respiratory-deficient mutants of Torulopsis glabrata, a yeast with circular mitochondrial deoxyribonucleic acid of 6 mu m. J Bacteriol 1976; 126: 959–968
   Google Scholar
• Kontoyiannis DP. Modulation of fluconazole sensitivity by the interaction of mitochondria and erg3p in Saccharomyces cerevisiae. J Antimicrob Chemother 2000; 46: 191–197
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999; 43: 2753–2765
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Calabrese D, Majcherczyk PA, Bille J. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999; 43: 2753–2765
   PubMed Web of Science ®Google Scholar
• Brun S, Berges T, Poupard P, et al. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother 2004; 48: 1788–1796
   PubMed Web of Science ®Google Scholar
• Defontaine A, Bouchara JP, Declerk P, et al. In vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. J Med Microbiol 1999; 48: 663–670
   PubMed Web of Science ®Google Scholar
• Hallstrom TC, Moye-Rowley WS. Multiple signals from dysfunctional mitochondria activate the pleiotropic drug resistance pathway in Saccharomyces cerevisiae. J Biol Chem 2000; 275: 37347–37356
   PubMed Web of Science ®Google Scholar
• Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother 2004; 48: 1773–1777
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Bille J. Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata. Antimicrob Agents Chemother 2001; 45: 1174–1183
   PubMed Web of Science ®Google Scholar
• Zhang X, Moye-Rowley WS. Saccharomyces cerevisiae multidrug resistance gene expression inversely correlates with the status of the F(0) component of the mitochondrial ATPase. J Biol Chem 2001; 276: 47844–47852
   PubMed Web of Science ®Google Scholar
• Kaur R, Castano I, Cormack BP. Functional genomic analysis of fluconazole susceptibility in the pathogenic yeast Candida glabrata: roles of calcium signaling and mitochondria. Antimicrob Agents Chemother 2004; 48: 1600–1613
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP. Efflux-mediated resistance to fluconazole could be modulated by sterol homeostasis in Saccharomyces cerevisiae. J Antimicrob Chemother 2000; 46: 199–203
   Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142
   PubMed Web of Science ®Google Scholar
• Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000; 44: 368–377
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Douglas C, Marrinan J, et al. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother 1994; 38: 2750–2757
   PubMed Web of Science ®Google Scholar
• Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997; 41: 2471–2479
   PubMed Web of Science ®Google Scholar
• Higashiyama Y, Kohno S. Micafungin: a therapeutic review. Expert Rev Anti Infect Ther 2004; 2: 345–355
   PubMedGoogle Scholar
• Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643–658
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003; 41: 5729–5731
   PubMed Web of Science ®Google Scholar
• Carver PL. Micafungin. Ann Pharmacother 2004; 38: 1707–1721
   PubMedGoogle Scholar
• Douglas CM, Foor F, Marrinan JA, et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. Proc Natl Acad Sci USA 1994; 91: 12907–12911
   PubMed Web of Science ®Google Scholar
• Douglas CM, Marrinan JA, Li W, Kurtz MB. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-beta-D-glucan synthase. J Bacteriol 1994; 176: 5686–5696
   PubMedGoogle Scholar
• Mazur P, Morin N, Baginsky W, et al. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol 1995; 15: 5671–5681
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Abruzzo G, Flattery A, et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infection & Immunity 1996; 64: 3244–3251
   PubMed Web of Science ®Google Scholar
• Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997; 41: 2471–2479
   PubMed Web of Science ®Google Scholar
• Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol 2002; 40: 2228–2230
   PubMed Web of Science ®Google Scholar
• Paderu P, Park S, Perlin DS. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother 2004; 48: 3845–3849
   PubMed Web of Science ®Google Scholar
• Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 3407–3411
   PubMed Web of Science ®Google Scholar
• Osherov N, May GS, Albert ND, Kontoyiannis DP. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002; 46: 2462–2469
   PubMed Web of Science ®Google Scholar
• Markovich S, Yekutiel A, Shalit I, Shadkchan Y, Osherov N. Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2004; 48: 3871–3876
   PubMed Web of Science ®Google Scholar
• Lesage G, Sdicu AM, Menard P, et al. Analysis of beta-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin. Genetics 2004; 167: 35–49
   PubMed Web of Science ®Google Scholar
• Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother 1983; 23: 79–85
   PubMed Web of Science ®Google Scholar
• Polak A, Wain WH. The effect of 5-fluorocytosine on the blastospores and hyphae of Candida albicans. J Med Microbiol 1979; 12: 83–97
   Google Scholar
• Kurtz JE, Exinger F, Erbs P, Jund R. New insights into the pyrimidine salvage pathway of Saccharomyces cerevisiae: requirement of six genes for cytidine metabolism. Curr Genet 1999; 36: 130–136
   Google Scholar
• Weber S, Polak A. Susceptibility of yeast isolates from defined German patient groups to 5-fluorocytosine. Mycoses 1992; 35: 163–171
   PubMedGoogle Scholar
• Stiller RL, Bennett JE, Scholer HJ, et al. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother 1982; 22: 482–487
   PubMed Web of Science ®Google Scholar
• Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 1987; 33: 381–395
   PubMed Web of Science ®Google Scholar
• Polak A. Combination therapy for systemic mycosis. Infection 1989; 17: 203–209
   PubMed Web of Science ®Google Scholar
• Polak A. Combination therapy in systemic mycosis. J Chemother 1990; 2: 211–217
   PubMed Web of Science ®Google Scholar
• Polak A. Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy 1978; 24: 2–16
   PubMed Web of Science ®Google Scholar
• Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 1982; 28: 461–479
   PubMed Web of Science ®Google Scholar
• Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother 2004; 48: 2223–2227
   PubMed Web of Science ®Google Scholar
• Pujol C, Pfaller MA, Soll DR. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother 2004; 48: 262–266
   Google Scholar
• Hope WW, Tabernero L, Denning DW, Anderson MJ. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother 2004; 48: 4377–4386
   PubMed Web of Science ®Google Scholar
• Montplaisir S, Drouhet E, Mercier-Soucy L. Sensitivity and resistance of pathogenic yeasts to 5-fluoropyrimidines. II.--Mechanisms of resistance to 5-fluorocytosine (5-FC) and 5-fluorouracil (5-FU) (author's transl)]. Ann Microbiol (Paris) 1975; 126B: 41–49
   Google Scholar
• Fasoli MO, Kerridge D, Morris PG, Torosantucci A. 19F nuclear magnetic resonance study of fluoropyrimidine metabolism in strains of Candida glabrata with specific defects in pyrimidine metabolism. Antimicrob Agents Chemother 1990; 34: 1996–2006
   PubMed Web of Science ®Google Scholar
• Kelly SL, Lamb DC, Kelly DE. Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett 1999; 180: 171–175
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha- demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother. 1998; 42: 241–253
   PubMed Web of Science ®Google Scholar
• Lamb D, Kelly DE, Hagen-Schunck W. The mutation T315A in Candida albicans sterol 14a-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem 1997; 272: 5682–5688
   PubMed Web of Science ®Google Scholar
• Lamb DC, Kelly DE, White TC, Kelly SL. The R467K amino acid substitution in Candida albicans sterol 14alpha- demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 2000; 44: 63–67
   PubMed Web of Science ®Google Scholar
• White T. The presence of R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14a-demethylase in Candida albicans. Antimicrob Agents Chemother 1997; 41: 1488–1494
   PubMed Web of Science ®Google Scholar
• Kelly SL, Lamb DC, Loeffler J, Einsele H, Kelly DE. The G464S amino acid substitution in Candida albicans sterol 14alpha- demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun 1999; 262: 174–179
   PubMed Web of Science ®Google Scholar
• Loffler J, Kelly SL, Hebart H, et al. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. Gene 1997; 192: 235–240
   Google Scholar
• Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 2004; 48: 2124–2131
   PubMed Web of Science ®Google Scholar
• Favre B, Didmon M, Ryder NS. Multiple amino acid substitutions in lanosterol 14alpha-demethylase contribute to azole resistance in Candida albicans. Microbiology 1999; 145: 2715–2725
   PubMed Web of Science ®Google Scholar